VRTX This isn’t simply “up again.”

After Vertex’s Q2, the market focus is clear: the company raised its 2026 revenue guidance, and expectations for its cystic fibrosis business/cash flow have been repriced. On-chain, $VRTXon is up about +7.8% over 24 hours, with trading volume around $1.427 billion, already pushing into the top spot for gains on bStocks.

My take is that this kind of big pharma RWA is different from both RWA and meme plays—short-term, it’s mainly about the “earnings expectation gap + U.S. stock market follow-through.” On-chain moving first is fine, but with only 21 holders and Top10 approaching 100%, the structure can’t be judged by price increases alone.

bStocks/tokenized stocks don’t equal direct share ownership; the 24/7 on-chain price and the U.S. stock market session may have price gaps, and issues like liquidity and the risk of chasing with a pullback should be prioritized.

Do you think this wave is the start of the pharma earnings storyline spreading, or is it just on-chain short-term sentiment that’s getting ahead of itself?

$VRTXon #bStocks #RWA